Oasmia Pharmaceutical AB. (8/10/20). "Press Release: Oasmia Pharmaceutical Appoints Peter Selin as Chief Business Officer". Uppsala.

	Organisation	Oasmia Pharmaceutical AB
	Organisation 2	Consilium Strategic Communications Ltd. (CSC)
	Today	ICR Consilium Strategic Communications
	Group	ICR (Group)
	Product	cancer drug
	Product 2	veterinary drug_o
	Person	Selin, Peter (Oasmia 202008– CBO before Inceptua Group + Swedish Orphan Biovitrum + Ernst & Young)
	Person 2	Martelet, Francois R. (Oasmia 202008 CEO before TopoTarget 201011 CEO)

Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces the appointment of Peter Selin as Chief Business Officer reporting directly to Dr. Francois R. Martelet, Chief Executive Officer.

Mr Selin has almost 20 years of business development experience, most recently serving as VP Pharma Business Operations at Inceptua Group, the pharmaceuticals company and services provider. During an extensive career including a number of senior roles, Mr Selin also gained experience in finance and strategic planning as well as contract negotiations and alliance management. His past roles include appointments at Sobi, where he served as VP Corporate Development and managed partnering and licensing activities and corporate strategy projects, as well as Manager, Strategy & Transformation at Ernst & Young.

Francois Martelet, M.D., CEO of Oasmia, commented: “We have conducted a thorough external search for this role and are delighted to have Peter joining the Oasmia team. His deep expertise in business development and strategy in the life science sector will be invaluable to Oasmia as we continue to pursue growth by seeking out M&A and licensing opportunities that complement our technology and business model.”

Peter Selin, newly appointed CBO of Oasmia, said: ”I am pleased to be joining Oasmia at an exciting time in the Company’s development. I look forward to working alongside the rest of the team and drawing on the experience I have gained over my career so far to advance Oasmia’s strategic goals.”

About Oasmia Pharmaceutical

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR17. Oasmia has been successful in moving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has received market authorization in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories. The company’s shares are traded on Nasdaq Stockholm (ticker: OASM). Visit www.oasmia.com for further information.

-ENDS-

For more information:

Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Michael af Winklerfelt, Chief Financial Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com

Consilium Strategic Communications
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com

Record changed: 2023-06-05